Diagnosis and management of bronchiolitis obliterans syndrome following lung or hematopoietic cell transplantation

K. Meyer

DOI: https://doi.org/10.1586/17476348.2016.1162717

2016-03-21

Expert Review of Respiratory Medicine

Abstract:Both allogeneic hematopoietic cell transplantation (HCT) and lung transplantation (LTX) can rescue patients from disorders with poor prognoses and allow improved quality of life and prolonged survival. However, patients who undergo HCT or LTX can develop lung function loss due to obliterative bronchiolitis (OB), which is characterized by small airway injury and inflammation that progresses to fibrosis and luminal obliteration that is irreversible. This post-transplant complication, which has been commonly referred to as bronchiolitis obliterans syndrome (BOS), is associated with high morbidity and mortality and usually leads to obstructive physiology with progressive lung function decline, impaired quality of life due to dyspnea and poor exercise tolerance, eventual need for chronic use of supplemental oxygen, and death due to respiratory failure.[1–3] Intensification of immunosuppression tends to provide only marginal benefit for recipients who develop BOS and significantly increases the risk of adverse events such as lifethreatening infections. Therefore, more effective therapies are much needed to treat this inflammatory/fibrotic process that primarily affects small airway bronchioles. Because OB is difficult to reliably detect without performing a surgical lung biopsy (e.g. via bronchoscopy with bronchoalveolar lavage and transbronchial lung biopsy), demonstration of a significant decline in forced expiratory volume in one second (FEV1) via pulmonary function testing (PFT) has been adopted as a surrogate marker for post-transplant lung function decline due to OB. A significant decline to ≤80% of stable posttransplant baseline FEV1 values that is not explained by potentially reversible, non-OB factors that can cause lung function impairment is considered diagnostic of BOS in LTX recipients.[3] Similarly, the diagnosis of BOS in HCT recipients requires a combination of airflow obstruction on PFT, evidence of air trapping by high-resolution computed tomography (HRCT) and/or increased residual lung volume, a non-OB manifestation of chronic graft-versus-host disease (cGVHD), and absence of an active pulmonary infection.[1,4] However, although histopathologic changes are similar for BOS in both HCT and LTX recipients, significant differences in incidence and prevalence, risk factors, pathophysiology, and management exist. Do key differences exist between HCT-BOS versus LTX-BOS?